$13.70
0.080.59%
At Close: -
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Perspective Therapeutics (AMEX:CATX) Stock, Analyst Ratings, Price Targets, Forecasts
Perspective Therapeutics Inc has a consensus price target of $6.46 based on the ratings of 7 analysts. The high is $24 issued by B of A Securities on July 25, 2024. The low is $1.4 issued by JonesTrading on November 15, 2023. The 3 most-recent analyst ratings were released by B of A Securities, RBC Capital, and Jones Trading on July 25, 2024, June 14, 2024, and May 16, 2024, respectively. With an average price target of $9.73 between B of A Securities, RBC Capital, and Jones Trading, there's an implied -28.95% downside for Perspective Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
RBC Capital
Jones Trading
B. Riley Securities
JonesTrading
1calculated from analyst ratings
Analyst Ratings for Perspective Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/25/2024 | Buy Now | 75.18% | B of A Securities | Alec Stranahan | → $24 | Initiates | → Buy | Get Alert |
| 06/25/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen | — | Reiterates | → Overweight | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen | — | Reiterates | → Overweight | Get Alert |
| 06/18/2024 | Buy Now | — | Oppenheimer | Jeff Jones | $2 → $19 | Reiterates | Outperform → Outperform | Get Alert |
| 06/18/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen | — | Reiterates | → Overweight | Get Alert |
| 06/14/2024 | Buy Now | -78.1% | RBC Capital | Gregory Renza | $30 → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2024 | Buy Now | -83.94% | Jones Trading | Justin Walsh | $15 → $22 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | -78.1% | RBC Capital | Gregory Renza | → $30 | Initiates | → Outperform | Get Alert |
| 05/09/2024 | Buy Now | — | Cantor Fitzgerald | Louis Chen | — | Initiates | → Overweight | Get Alert |
| 04/09/2024 | Buy Now | -87.59% | B. Riley Securities | Yuan Zhi | $12 → $17 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | -89.05% | Oppenheimer | Jeff Jones | $12 → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 03/19/2024 | Buy Now | -91.24% | Oppenheimer | Jeff Jones | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 01/26/2024 | Buy Now | -91.24% | B. Riley Securities | Yuan Zhi | → $12 | Initiates | → Buy | Get Alert |
| 11/15/2023 | Buy Now | -89.78% | JonesTrading | Justin Walsh | → $14 | Initiates | → Buy | Get Alert |
| 05/19/2023 | Buy Now | -91.24% | Oppenheimer | Jeff Jones | $10 → $12 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Perspective Therapeutics (CATX) stock?
The latest price target for Perspective Therapeutics (AMEX:CATX) was reported by B of A Securities on July 25, 2024. The analyst firm set a price target for $24.00 expecting CATX to rise to within 12 months (a possible 75.18% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Perspective Therapeutics (CATX)?
The latest analyst rating for Perspective Therapeutics (AMEX:CATX) was provided by B of A Securities, and Perspective Therapeutics initiated their buy rating.
When was the last upgrade for Perspective Therapeutics (CATX)?
There is no last upgrade for Perspective Therapeutics
When was the last downgrade for Perspective Therapeutics (CATX)?
There is no last downgrade for Perspective Therapeutics.
When is the next analyst rating going to be posted or updated for Perspective Therapeutics (CATX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Perspective Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Perspective Therapeutics was filed on July 25, 2024 so you should expect the next rating to be made available sometime around July 25, 2025.
Is the Analyst Rating Perspective Therapeutics (CATX) correct?
While ratings are subjective and will change, the latest Perspective Therapeutics (CATX) rating was a initiated with a price target of $0.00 to $24.00. The current price Perspective Therapeutics (CATX) is trading at is $13.70, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.